| | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C31H31N5O2S2 |
| Molar mass | 569.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SRT-3025 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. It has been investigated as a potential treatment for osteoporosis, [1] [2] [3] [4] [5] and anemia. [6] [7]